Of anti-M lerian hormone (AMH) in Leydig cells remains a bit of an anomaly since AMH expression has traditionally been associated with Sertoli cell tumors rather than Leydig cell tumors [18] and AMH expression in get I-CBP112 normal cells is widely believed to be confined to Sertoli cells and not toAguilar et al. Journal for ImmunoTherapy of Cancer (2017) 5:Page 11 ofLeydig cells [34?7]. However, the AMH-SV40Tag transgene is clearly expressed in both Leydig cells and Sertoli cells of SJL.AMH-SV40Tag transgenic mice (Fig. 4e) thereby implying that both cell types may express AMH and that transgene expression of SV40Tag may predispose to creation of tumors of either cell type with Sertoli cell tumors predominating in the original AT-t94 transgenic mouse generated in the C57BL/6 (H-2b) background strain and Leydig cell tumors predominating when the AMH-SV40Tag transgene is expressed in the SJL/J (H-2s) background strain. Indeed, strain-specific predispositions may occur as a result of differential PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28607003 epigenetic factors that are capable of shaping genetic outcomes [38]. TSC tumors of the testis comprise less than 5 of testicular cancers, and this rareness predisposes to being overlooked with respect to developing and testing new therapies for such uncommon tumors [3]. However, stage I TSC tumors have 5 year overall survivals that are significantly lower compared to those of stage I germ cell tumors that represent the vast majority of human testicular cancers [3]. Thus, though relatively rare, the enhanced lethality of TSC tumors begs for an improvement in treatment and clinical control. The results of our current study indicate that inhibin- vaccination may be useful and effective as an adjuvant therapy for TSC tumors particularly since the vast majority of TSC tumors express inhibin- [5?] and that these tumors occur in young men in the prime of their life at a median age of 43 years [3].Acknowledgements The authors wish to thank Dr. Ritika Jaini, Department of Genomic Medicine, Cleveland Clinic, Cleveland, OH for her technical assistance and advice. Funding This work was generously supported by a grant from the Andrew and Lillian A. Posey Foundation (VKT). The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the Lillian A. Posey Foundation. The funding organization played no role in the design of the study, in the collection, analysis, and interpretation of data, or in writing the manuscript. Availability of data and materials The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Authors’ contributions RA was involved in all aspects of the study including experimental design, performance of the experiments, data analysis, and preparation of the manuscript. JMM provided expert technical assistance throughout the study and was particularly instrumental in providing oversight in developing the recombinant inhibin- protein and providing technical assistance with molecular assays and data collection. PB provided expert technical assistance particularly with respect to flow cytometry analysis. VKT participated in experimental design, data analysis, interpretation, design and production of figures, manuscript preparation, and obtaining financial support for the project. All authors read and approved the final manuscript. Authors’ information Not applicable. Competing interests The authors declare that they have.